Passage Bio to Participate in Upcoming Investor Conferences
01 août 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
31 juil. 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
05 juin 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
11 mai 2023 07h00 HE
|
Passage Bio
On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023Submitted protocol amendment to regulatory...
Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
04 mai 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, May 04, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 avr. 2023 16h01 HE
|
Passage Bio
PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
17 avr. 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
27 mars 2023 07h00 HE
|
Passage Bio
PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
06 mars 2023 07h00 HE
|
Passage Bio
Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial...
Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program
01 mars 2023 07h00 HE
|
Passage Bio
$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or universityScholarship application deadline is April 1 for the initial...